Price
CHART BY
Frequently asked questions
What is Metsera, Inc.'s market capitalization?
The market capitalization of Metsera, Inc. is €4.76B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What are the analyst ratings and target price for Metsera, Inc.'s stock?
Currently, 3 analysts cover Metsera, Inc.'s stock, with a consensus target price of €47.74. Analyst ratings provide insights into the stock's expected performance.
How many employees does Metsera, Inc. have, and what sector and industry does it belong to?
Metsera, Inc. employs approximately 81 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Metsera, Inc.'s shares?
The free float of Metsera, Inc. is 48.00M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- €4.76B
- Free Float
- 48.00M
Pricing
- 52W span
- €11.20€46.14
Analyst Ratings
The price target is €47.74 and the stock is covered by 3 analysts.
Buy
1
Hold
2
Sell
0
Information
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.
- Employees
- 81
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- MTSR
Fundamentals & EOD data from FactSet